Meeting
2022 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
Authors
Ian Chau
Royal Marsden Hospital, London & Surrey, United Kingdom
Ian Chau , Jaffer A. Ajani , Yuichiro Doki , Jianming Xu , Lucjan Wyrwicz , Satoru Motoyama , Takashi Ogata , Hisato Kawakami , Chih-Hung Hsu , Antoine Adenis , Farid El Hajbi , Maria Di Bartolomeo , Maria Ignez Freitas Melro Braghiroli , Eva Holtved , Mariela A. Blum Murphy , Sandzhar Abdullaev , Samira Soleymani , Ming Lei , Ken Kato , Yuko Kitagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03143153
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4035)
DOI
10.1200/JCO.2022.40.16_suppl.4035
Abstract #
4035
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648.
First Author: Ian Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.
First Author: Kunihiro Fushiki
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
First Author: Dirk Schadendorf